Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Femasys Inc.

< Previous 1 2 3 Next >
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY PMCB
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. EU MDR Final Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.